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Objective To study the clinical significance of a nested polymerase chain reaction (PCR) method compared to
immunofluorescence (IF) for detection of Pneumocystis carinii.
Methods The medical records of 89 patients with 91 episodes of pneumonia were scrutinised retrospectively.
The pneumonia episodes were divided into categories according to the likelihood that the patient had had
clinical Pneumocystis carinii pneumonia (PCP). All respiratory tract samples from the 89 patients (34 broncho-
alveolar lavage (BAL) and 57 sputa) were tested for Pneumocystis carinii by IF and nested PCR.
Results Fifteen episodes, as diagnosed by IF, were classified as true PCP (combination of the groups with
definite and probable PCP; sensitivity 60%, specificity 97%). Among the P. carinii DNA-positive episodes,
detected with nested PCR, 24 were classified as true PCP (combination of the groups with definite and
probable PCP; sensitivity 96%, specificity 59%), since all IF-positive samples were nested PCR positive. Only
one pneumonia episode classified as a probable PCP, was negative with both methods, as applied to a BAL
sample.
Conclusions IF applied to BAL or sputum seems to be the most specific method for diagnosis of clinical PCP.
Additional clinical cases can be found by nested PCR, although this then gives a high risk of detecting
subclinical colonisation of P. carinii.
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INTRODUCTION
Pneumocystis carinii is a fungal organism that causes Pneumocystis
carinii pneumonia (PCP), a life-threatening condition in immu-
nosuppressed patients. The current laboratory diagnosis of PCP
is dependent on microscopic demonstration of the organism by
cytochemical staining or by direct/indirect immunofluorescent
(IF) staining with anti-Pneumocystis monoclonal antibodies [1].
It has been previously demonstrated that the polymerase chain
reaction (PCR) is more sensitive than morphological examina-
tion for the detection of P. carinii [2–4], particularly in sputum
samples from patients receiving anti-PCP prophylaxis [2, 3].
Wehave also shown that the presence of P. carinii DNA is a
predictor for later development of manifest PCP in human
immunodeficiency virus (HIV)-infected patients [5]. Among
non-HIV-infected patients, however, we found that clinical
PCP did not develop in many of the patients in whom P. carinii
had been detected by nested PCR. This was not the case with
the IF test. A study was therefore conducted to assess the clinical
value of a nested PCR method compared with IF.
MATERIALS AND METHODS
Study population
Over a 32-month period, between January 1996 and August
1998, patients were admitted to the O¨rebro Medical Center
Hospital and treated for pneumonia, which was suspected to be
PCP. Respiratory tract specimens were sent to the Swedish
Institute for Infectious Disease Control (SMI) in Stockholm for
laboratory diagnosis. This was the basis for the present study,
which comprised a total of 91 samples [34 bronchoalveolar
lavage (BAL) samples and 57 induced sputa], representing 91
suspected episodes of PCP in 89 patients. The samples were
obtained from patients in different hospital departments,
although a specialist in infectious diseases was consulted in
the majority of the cases. The primary diseases of all the patients
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(age range: 16–87 years) are presented in Table 1. All samples
were primarily investigated by IF and if they were found to be
negative then nested PCR amplification was performed. Later,
nested PCR amplification was also performed on all IF-positive
samples.
Immunofluorescence
The IF method is based on a mouse monoclonal antibody
to Pneumocystis carinii and fluorescein isothiocyanate-conjugat-
ed sheep anti-mouse immunoglobulin as described by Elvin
et al. [1].
PCR
The preparation of DNA from sputum and BAL pellets has been
described elsewhere [6]. The nested PCR assay was performed
with the use of the outer primers pAZ102-H and pAZ102-E,
the inner primers pAZ102-X/R1 and pAZ102-Y/R1 and a
method based on a protocol by Wakefield [7], with some
modifications: namely, the first PCR was carried out with
35 cycles and without initial denaturation; the nested PCR
was initiated with a denaturation step at 94 8C for 10 min; and
15 cycles instead of 30 were performed in the second cycling
stage. Two per cent (vol./vol.) of the first PCR product was
used as template in the nested PCR reaction and both the
reaction mixes contained 0.0125 U AmpliTaq/Gold (Applied
Biosystems, Stockholm, Sweden) per ml instead of Taq poly-
merase. The PCR reaction mixes were kept at40 8C until use.
All the DNA preparations were checked for their content and
inhibition using a PCR method, based on amplification of a
portion of the human b-globin gene [8].
Clinical classification
The retrospective clinical diagnoses of PCP in all the cases in the
study were assessed by an interpretation of the medical and
laboratory records of each individual patient. On the basis of the
patient history, laboratory results and cultures, X-ray findings
and the effect of cotrimoxazole therapy, the episodes were
classified into five groups.
Definite PCP typical symptoms such as dyspnea, dry cough,
fever, typical chest X-ray with interstitial infiltration, negative
cultures of blood, BAL fluid and sputum, and successful mono-
therapy treatment with cotrimoxazole.
Table1 Primary diseases, clinical classification and the results of immunofluorescence (IF) and nested polymerase chain reaction (PCR), in all patients evalu-
ated for Pneumocystis cariniipneumonia (PCP) at O« rebro Medical Center Hospital from1996 to1998
No. of
surveyed
Episodes with positive laboratory results Clinically positive PCPa
Disease episodes Total IFþ/PCRþ IF^/PCRþ Total IFþ/PCRþ IF^/PCRþ
Lymphoblastic and
lymphocytic leukemia
15 10 3 7 8b 3 5
Vasculitis 14 9 3 6 4 3 1
HIV infection 13 8 5 3 6 5 1
Lymphoma 12 7 3 4 2c 2 0
Myeloid leukemia 7 2 0 2 0 0 0
Multiple myeloma 4 3 0 3 1 0 1
Rheumatoid arthritis 3 3 1 2 1 1 0
Prostate cancer 2 2 1 1 1 1 0
Systemic lupus erythematosus 2 2 0 2 0 0 0
Myelodysplastic syndrome 1 1 0 1 1 0 1
Other diagnosis with positive
laboratory resultsd
4 4 1 3 0 0 0
Dermatomyositis 1 0 0 0 1 0 0
Other diagnosis with negative
laboratory resultse
13 0 0 0 0 0 0
Total 91 51 17 34 25 15 9
a Corresponds to the classifications definite and probable PCP (seeTable 2).
b B-chronic lymphocytic leukemia, six episodes;T-acute lymphoblastic leukemia, two episodes.
c B-cell non-Hodgkin’s lymphoma, one episode; B- andT-cell non-Hodgkin’s lymphoma, one episode.
d Cholangiocarcinoma, one episode;Waldenstro« m’s macroglobulinaemia, one episode; idiopathic thrombocytopenic purpura, one episode; bronchiolitis oblit-
erans organising pneumonia, one episode.
e Unclear pulmonary infiltrates, five episodes; lung cancer, three episodes; postoperative pneumonia, two episodes; chronic obstructive pulmonary disease,
one episode; testicular cancer, one episode; cystic fibrosis, one episode.
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Probable PCP typical symptoms, variant chest X-ray, negative
cultures and successful treatment with cotrimoxazole in com-
bination with cephalosporin or erythromycin.
Non-probable PCP atypical symptoms, negative respiratory tract
cultures and clinical improvement or cure after cephalosporin or
erythromycin treatment.
No PCP atypical symptoms, positive respiratory tract cultures
and successful treatment with cephalosporin or erythromycin,
or in the event of death, negative histological examination of
the lung parenchyma for PCP.
Unclear: Two patients were treated with cotrimoxazole but died
within a few days. Laboratory results, including pathological
anatomical diagnosis (PAD), were inconclusive and it was not
possible to classify the patients.
In most cases the cotrimoxazole therapy had been initiated
before the IF and PCR results became available.
RESULTS
The results of the laboratory tests for Pneumocystis carinii detec-
tion in relation to the patients PCP status, as evaluated from the
medical and laboratory records, are presented in Tables 1–3.
Fifteen samples that were positive for P. carinii at IF, were
considered to represent either a definite or a probable PCP
(Tables 1 and 2), whereas a total of 24 of the nested PCR-
positive episodes were classified as a definite or probable PCP,
since all IF-positive samples were also nested PCR-positive.
Out of the 34 patients with positive nested PCR and negative
IF, only nine (26%) were found to have had definite or prob-
able PCP.
The performance of the laboratory tests in terms of statistical
values, in the total specimens and in BAL and sputum separately,
is presented in Table 3, using the clinical classification as our
diagnostic standard and considering definite and probable PCP
as being truly positive. In total, IF had a sensitivity of 60% and a
specificity of 97%, while the corresponding values for nested
PCR were 96% and 59%, respectively. One episode, evaluated
Table 2 Retrospective clinical classification of patients from O« rebro Medical Center Hospital, Sweden in relation to the laboratory results for Pneumocystis













Definite PCP 10 (4; 6) 3 (1; 2) 0 (0; 0)
Probable PCP 5 (2; 3) 6 (0; 6) 1 (1; 0)
Non-probable PCP 1 (1; 0) 7 (3; 4) 4 (1; 3)
No PCP 1 (0;1) 17 (6;11) 34 (13b; 21)
Unclear 0 (0; 0) 1 (1; 0) 1 (1; 0)
Total 17 (7;10) 34 (11; 23) 40 (16; 24)
BAL, bronchoalveolar lavage.
a Therewas no episode of IFþ/PCR^ in the study.
b In one of these patients the sputumwas also examined.
PCP, Pneumocystis cariniipneumonia.
Table 3 Performance of the immunofluorescence and nested polymerase chain reaction tests for the diagnosis of Pneumocystis carinii pneumonia (PCP),
using the clinical classification as our diagnostic standard and considering definite PCPand probable PCPas truly positive
Predictive value
Test Sensitivity (%) Specificity (%) Positive (%) Negative (%)
Immunofluorescence
Total 15/25 (60) 62/64 (97) 15/17 (88) 62/72 (86)
BAL 6/8 (75) 23/24 (96) 6/7 (86) 23/25 (92)
Sputum 9/17 (53) 39/40 (98) 9/10 (90) 39/47 (83)
Polymerase chain reaction
Total 24/25 (96) 38/64 (59) 24/50 (48) 38/39 (97)
BAL 7/8 (88) 14/24 (58) 7/17 (41) 14/15 (93)
Sputum 17/17 (100) 24/40 (60) 17/33 (52) 24/24 (100)
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from a BAL sample, which was found to be negative with both
methods, was considered to be a probable PCP (Table 2),
whereas the remaining episodes with P. carinii-negative labora-
tory results were classified as cases of non-probable or no PCP.
DISCUSSION
To evaluate the clinical value of a nested PCR method com-
pared with IF for diagnosis of Pneumocystis carinii infection, the
medical and laboratory records of 89 patients, sampled for P.
carinii, were studied retrospectively. Every potential PCP epi-
sode was evaluated carefully by experienced specialists in infec-
tious diseases, resulting in one of the five clinical classifications
described (Table 2).
IF applied to BAL or induced sputum samples is considered
to be the standard for laboratory diagnosis of P. carinii infection.
The present study has clearly demonstrated that IF is the most
specific method for detecting clinical PCP in immunosup-
pressed patients. The IF method in use at our laboratory detects
both known stages of P. carinii [1]. The method is particularly
useful for induced sputum samples, in which the smaller trophic
cells (formerly the trophozoite stage) of P. carinii are more
abundant than the ascus stage (formerly the cyst stage) of the
organism. In our experience, the two P. carinii forms are
generally present in equal amounts in BAL samples. In addition,
the IF method has a general advantage over nucleic-acid-based
methods, since with IF it is possible to count the number of
alveolar macrophages in the sample and thus judge how repre-
sentative it is.
The retrospective evaluation of the medical records corre-
sponding to the 34 P. carinii DNA-positive samples that were all
negative at IF, resulted in a total of nine definite or probable
PCP episodes, yielding lower values of specificity and positive
predictive value (PPV) than IF. Thus, the overall majority of the
episodes in this group of patients were considered as non-
probable PCP or no PCP. This outcome is probably due to a
subclinical P. carinii colonisation of these patients, detected by
the very sensitive nested PCR method. The single pneumonia
episode that was considered as a probable PCP in a patient with
P. carinii-negative laboratory results can be explained by delayed
sampling; the sample was drawn 4 days after initiation of high-
dose treatment with cotrimoxazole (Tables 1 and 2).
Among the eight patients with leukemia who were consid-
ered to have definite or probable PCP, six had B-chronic
lymphocytic leukemia (B-CLL) and two had T-acute lympho-
blastic leukemia (Table 1). The group with B-CLL was larger
than expected, although four episodes were classified as prob-
able PCP and only two as definite. Most reported cases of PCP
are in patients with a compromised T-cell arm of their immune
function, caused by a disease such as leukemia, HIV infection,
or treatment with chemotherapy and immunosuppressive
drugs, including corticosteroids. There are very few reports
of patients with humoral defects and intact T-cell immunity
developing PCP [9]. It is therefore likely that the B-CLL
patients developed PCP as a result of a defective cell-mediated
immunity, caused by treatment. At O¨rebro Medical Center
Hospital, PCP prophylaxis is given to patients in known risk
groups, such as bone marrow transplant recipients and patients
treated with purine analogs. None of the eight leukemia patients
that were considered to have PCP in this study had undergone
either of these treatments or received PCP prophylaxis.
Pneumocystis carinii is now considered to be an organism that
will cause a new infection in the human host, rather than
reactivation of a latent infection, since Keely et al. demonstrated
that genetically distinct isolates are associated with separate PCP
episodes in HIV-infected patients [10]. This is supported by the
failure to find P. carinii with sensitive IF and PCR methods in
lung samples from healthy immunocompetent individuals [11,
12]. However, subclinical colonisation of P. carinii in non-HIV-
infected patients has previously been reported [2, 13–15], and
the present study confirms these observations. Recently, Nevez
and colleagues demonstrated a link between the level of CD4þ
cells, critical for immunodeficiency, and P. carinii colonisation in
HIV-negative patients [16]. A few reports have described the
presence of P. carinii in individuals without HIV infection or
immunodeficiency, namely adults with chronic obstructive
pulmonary disease [17] and children admitted with exacerba-
tions of chronic lung disorders [18]. In the former group, P.
carinii was detected by morphological methods to a carrier
prevalence of 10%, whereas with nested PCR it was detected
in 12 out of 36 specimens from children with chronic lung
disorders. Ten of these 12 PCR-positive samples were con-
firmed by morphological methods and six of the infected
children improved with cotrimoxazole therapy. In a recently
published retrospective study of the value of PCR for diagnos-
ing P. carinii, Sing et al. found, in agreement with our results, that
PCR frequently produced false-positive results in non-HIV-
immunocompromised patients [19]. In addition, they observed
using nested PCR that a significant percentage (17%) of
immunocompetent non-PCP patients were colonised with
clinically silent P. carinii.
Pneumocystis carinii colonisation may persist in humans and
the epidemiological implications of this phenomenon are not
yet known. The colonised patients may represent a reservoir for
transmission of the human form of P. carinii, at least in indoor
environments, such as hospital wards. We [20] and others [21]
have studied P. carinii transmission by examining P. carinii
genotypes in isolates from clustered PCP cases in hospitals,
but in none of the studies was predominant person-to-person
transmission of P. carinii demonstrated.
The present retrospective study has some methodological
limitations, e.g. the risk of bias, since the laboratory results were
known before the medical records of the patient population
were evaluated. However, the medical records of the patients in
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this study were carefully scrutinised on site, at the hospital to
which the patients were admitted. Moreover, the clinical
evaluations were performed by two clinicians completely inde-
pendently of, and free from, any loyalty to the diagnostic
laboratory (SMI). Regarding cotrimoxazole therapy, we con-
sider that the knowledge of the outcome of this treatment
influenced the investigators to only a limited extent.
A prospective, blind study among HIV-infected patients was
recently published, in which the clinical diagnosis of PCP based
on the morphological detection of P. carinii was compared with
that based on PCR amplification [22]. The authors found
reproducible concordance between the clinical picture of the
infection and the PCR results and only a few cases of probable
colonisation with P. carinii. This study differs from ours in two
main points. First, the study consisted only of HIV-infected
patients, who in general have a higher infectious load of P. carinii
than non-HIV patients, and second, only BAL samples were
used for the morphological diagnosis, which would generate a
higher yield of P. carinii for diagnostic purposes.
The most promising diagnostic role of PCR is in the detec-
tion of P. carinii in non-invasive sample materials. Helweg-
Larsen and colleagues found that a single-step ‘touchdown’
PCR had high sensitivity and specificity for detection of P.
carinii in oral wash specimens [23]. Using the present nested
PCR method, we have been able to detect P. carinii in naso-
pharyngeal aspirates from infants with suspected PCP (Olsson,
unpublished observations). In addition, the high level of sensi-
tivity and negative predictive value (NPV), for both BAL and
sputum samples, indicates that the nested PCR method can be
used to exclude a suspected P. carinii infection. With regard to
the cost, time, equipment and training of staff for the two
methods described in this study, the differences are marginal.
The PCR method, however, and in particular the nested
application of PCR, requires space resources; three to four
separate laboratories are needed to avoid contamination.
In conclusion, we found IF to be the most accurate method
for diagnosing clinical PCP in induced sputum or BAL samples.
Using nested PCR, additional clinical PCP cases can be diag-
nosed, but there is then an obvious risk of detecting subclinical
colonisation by P. carinii. These problems might be solved with a
quantitative PCR. In the absence of such a method, more
restrictive use of nested PCR on BAL and sputum samples is
recommended. For the diagnostic laboratory it may be appro-
priate to include a note with the laboratory result stating that
PCR-detected P. carinii may represent a clinical PCP or may
indicate subclinical colonisation by P. carinii in the host.
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